UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.94% | 33.23% | -13.91% | -16.88% | -58.46% |
| Total Depreciation and Amortization | 6.26% | 7.21% | 19.92% | 62.42% | 15.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.31% | 43.92% | 15.87% | -60.65% | 50.89% |
| Change in Net Operating Assets | -14.92% | -353.99% | 416.34% | -111.90% | 261.85% |
| Cash from Operations | 9.33% | -6.14% | 5.23% | -208.57% | 50.77% |
| Capital Expenditure | 80.46% | 38.30% | -220.45% | 61.74% | -19.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.91% | 10.29% | 210.14% | -142.67% | 156.95% |
| Cash from Investing | -11.72% | 10.53% | 209.41% | -142.83% | 156.79% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 301.04% | 2,723.21% | 761.76% | -52.11% | -99.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | 278.58% | 2,694.59% | 770.59% | -52.11% | -99.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 896.46% | 76.63% | 83.63% | -244.36% | 149.65% |